{
    "name": "daprodustat",
    "comment": "Rx",
    "other_names": [
        "Jesduvroq"
    ],
    "classes": [
        "Hypoxia-Inducible Factors Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/jesduvroq-daprodustat-4000303",
    "pregnancy": {
        "common": [
            "Available data are insufficient in pregnant females to establish a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes "
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Oral administration to pregnant rats and rabbits during organogenesis was associated with adverse fetal outcomes (eg, embryonic and fetal loss, reduced fetal weight) at doses that caused maternal toxicity and polycythemia ",
                    "Advise pregnant females regarding potential risk to fetus "
                ]
            },
            {
                "type": "Clinical consideration",
                "description": [
                    "CKD during pregnancy increases risk for maternal hypertension, preeclampsia, miscarriage, stillbirth, preterm delivery, low birth weight infants, and polyhydramnios "
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on drug presence in human milk, effects on breastfed infants, or effects on milk production ",
            "Daprodustat is present in the milk of lactating rats",
            "When a drug is present in animal milk, it is likely that drug will be present in human milk",
            "Advise patients not to breastfeed during treatment and for 1 week after final dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Increased risk of death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access",
                    "description": [
                        "Increased risk of thrombotic vascular events, including major adverse cardiovascular events (MACE) ",
                        "Hemoglobin rise >1 g/dL over 2 weeks may contribute to these risks ",
                        "Target hemoglobin level >11 g/dL is expected to further increase risk of death and arterial venous thrombotic events, as occurs with erythropoietin-stimulating agents (ESAs), which also increase erythropoietin levels ",
                        "No trial has identified a hemoglobin target level, daprodustat dose, or dosing strategy that avoids these risks ",
                        "Use lowest dose to reduce need for red blood cell transfusion ",
                        "Avoid use in patients with a history of myocardial infarction, cerebrovascular event, or acute coronary syndrome within 3 months before starting "
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Strong CYP2C8 inhibitors (eg, gemfibrozil) ",
                "Uncontrolled hypertension"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Increased risk of cardiovascular mortality, stroke, thromboembolism, serious acute kidney injury, hospitalization for heart failure, and serious gastrointestinal erosions observed",
                "Advise patients to seek immediate medical attention if signs or symptoms of MI, stroke, VTE, or thrombosis of vascular access develop; evaluate and manage promptly if these occur (see Black Box Warning)",
                "Hospitalization for heart failure reported; consider patientâ€™s history of heart failure before prescribing; advise patients on signs and symptoms of heart failure and to immediately their healthcare provider if these symptoms worsen",
                "Contraindicated in uncontrolled hypertension; periodically monitor blood pressure and adjust or initiate antihypertensive therapy as needed",
                "Safety not established for treatment of anemia due to CKD in adults not on dialysis; use not recommended in this setting",
                "Not studied and not recommended in patients with active malignancies; malignancies reported"
            ],
            "specific": [
                {
                    "type": "Gastrointestinal erosion",
                    "description": [
                        "Gastric or esophageal erosions occurred",
                        "Consider this risk particularly in patients with risk factors for gastrointestinal (GI) erosions, such as history of GI erosion, peptic ulcer disease, concomitant use of medications that increase the risk of GI erosion, current tobacco smoking, and alcohol use",
                        "Advise patients of symptoms and signs of gastric and esophageal erosions and of GI bleeding and to seek prompt medical care if these occur"
                    ]
                },
                {
                    "type": "Drug interaction overview ",
                    "description": [
                        "CYP2C8 substrate",
                        "Strong CYP2C8 inhibitors (eg, gemfibrozil)",
                        "Contraindicated",
                        "Strong CYP2C8 inhibitors are contraindicated due to marked increase in daprodustat exposure ",
                        "Moderate CYP2C8 inhibitors (eg, clopidogrel)",
                        "Reduce daprodustat dose by half when initiating moderate CYP2C8 inhibitors, except with a starting dose of 1 mg/day",
                        "Monitor Hgb and adjust daprodustat dose when initiating or stopping moderate CYP2C8 inhibitor ",
                        "Moderate CYP2C8 inhibitors increase daprodustat exposure",
                        "CYP2C8 inducers (eg, rifampin)",
                        "Monitor Hgb and adjust dose when initiating or stopping therapy with CYP2C8 inducers during treatment",
                        "CYP2C8 inducers may decrease exposure and efficacy of daprodustat "
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Hypertension",
            "percent": "24"
        },
        {
            "name": "Abdominal pain",
            "percent": "11"
        },
        {
            "name": "Dizziness",
            "percent": "7"
        },
        {
            "name": "Hypersensitivity",
            "percent": "7"
        },
        {
            "name": "Vascular access thrombosis",
            "percent": "5"
        },
        {
            "name": "Myocardial infarction",
            "percent": "3.4"
        },
        {
            "name": "Stroke",
            "percent": "1.2"
        },
        {
            "name": "Deep vein thrombosis",
            "percent": "0.7"
        },
        {
            "name": "Pulmonary embolism",
            "percent": "0.3"
        }
    ]
}